Minerva Neurosciences, Inc.
NERV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001598646
No open-market purchases or sales by Minerva Neurosciences, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $234.8M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Minerva Neurosciences, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 33 | 1 | 47 | +15 |
| Shares | 23.1M | 252.0K | 39.2M | +16.4M (+71.7%) |
| Value | $107.7M | $1.01M | $236.1M | +$129.4M (+121.3%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Minerva Neurosciences, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Balyasny Asset Management LLC | 4,258,600 | $25.7M | 0.05% |
| Foresite Capital Management VI LLC | 1,986,600 | $12.0M | 2.60% |
| Vanguard Capital Management LLC | 1,845,831 | $11.1M | 0.00% |
| Trails Edge Capital Partners, LP | 1,419,000 | $8.55M | 2.01% |
| Seven Fleet Capital Management LP | 1,137,730 | $6.85M | 2.15% |
| DV Trading LLC | 889,254 | $5.36M | 0.49% |
| Vanguard Fiduciary Trust Co | 264,047 | $1.59M | 0.00% |
| Marshall Wace, LLP | 218,759 | $1.32M | 0.00% |
| Susquehanna International Group, LLP | 119,131 | $717.8K | 0.00% |
| Northern Trust Corp | 93,308 | $562.2K | 0.00% |
| Brendel Financial Advisors LLC | 41,799 | $251.8K | 0.12% |
| Goldman Sachs Group Inc | 32,012 | $192.9K | 0.00% |
| Charles Schwab Investment Management Inc | 31,000 | $186.8K | 0.00% |
| Brevan Howard Capital Management LP | 28,629 | $172.5K | 0.00% |
| Vanguard Global Advisers, LLC | 23,853 | $143.7K | 0.00% |
| Cannon Global Investment Management, LLC | 17,758 | $107.0K | 0.26% |
| Omers Administration Corp | 10,300 | $62.1K | 0.00% |
| Barclays PLC | 146 | $880 | 0.00% |
Sold out (3)
Institutions that held Minerva Neurosciences, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Lion Point Capital, LP | 35,000 | $140.7K |
| Deutsche Bank AG | 1,500 | $6.03K |
| Tower Research Capital LLC (TRC) | 501 | $2.01K |
Not filed for Q1 2026 yet (1)
Institutions that held Minerva Neurosciences, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 252,029 | $1.01M |